Human Biodistribution and Dosimetry of 11C-CUMI-101, an Agonist Radioligand for Serotonin-1A Receptors in Brain
2011

Radiation Exposure from 11C-CUMI-101 in Brain Imaging

Sample size: 9 publication 10 minutes Evidence: moderate

Author Information

Author(s): Hines Christina S., Liow Jeih-San, Zanotti-Fregonara Paolo, Hirvonen Jussi, Morse Cheryl, Pike Victor W., Innis Robert B.

Primary Institution: Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland, United States of America

Hypothesis

The study aims to calculate the radiation exposure to organs of the body based on whole-body imaging with 11C-CUMI-101 in healthy volunteers.

Conclusion

The effective dose of 11C-CUMI-101 is 5.3±0.5 microSv/MBq, which is comparable to other 11C-labeled ligands for brain imaging.

Supporting Evidence

  • The effective dose of 11C-CUMI-101 was found to be 5.3±0.5 microSv/MBq.
  • Peak brain uptake of 11C-CUMI-101 was about 11% IA at 10 minutes post-injection.
  • The liver had the highest uptake of radioactivity, reaching about 35% IA by the end of the scan.
  • Three of the nine subjects had transiently elevated plasma CK after injection, but these were asymptomatic.

Takeaway

This study looked at how much radiation people get from a brain imaging drug called 11C-CUMI-101, and found it's safe to use.

Methodology

Nine healthy volunteers were injected with 11C-CUMI-101 and imaged using PET to calculate radiation doses to various organs.

Potential Biases

Potential bias in participant selection as only healthy volunteers were included.

Limitations

The study was limited to a small sample size of healthy volunteers, which may not represent broader populations.

Participant Demographics

Nine healthy volunteers, five males and four females, average age 36 years.

Digital Object Identifier (DOI)

10.1371/journal.pone.0025309

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication